PMID- 22935464
OWN - NLM
STAT- MEDLINE
DCOM- 20121102
LR  - 20151119
IS  - 1558-3597 (Electronic)
IS  - 0735-1097 (Linking)
VI  - 60
IP  - 10
DP  - 2012 Sep 4
TI  - Progression of myocardial fibrosis assessed with cardiac magnetic resonance in 
      hypertrophic cardiomyopathy.
PG  - 922-9
LID - 10.1016/j.jacc.2012.03.076 [doi]
AB  - OBJECTIVES: This study sought to assess the rate of progression of fibrosis by 2 
      consecutive cardiac magnetic resonance (CMR) examinations and its relation with 
      clinical variables. BACKGROUND: In hypertrophic cardiomyopathy (HCM) myocardial 
      fibrosis, detected by late gadolinium enhancement (LGE), is associated to a 
      progressive ventricular dysfunction and worse prognosis. METHODS: A total of 55 
      HCM patients (37 males; mean age 43 +/- 18 years) underwent 2 CMR examinations 
      (CMR-1 and CMR-2) separated by an interval of 719 +/- 410 days. Extent of LGE was 
      measured, and the rate of progression of LGE (LGE-rate) was calculated as the 
      ratio between the increment of LGE (in grams) and the time (months) between the 
      CMR examinations. RESULTS: At CMR-1, LGE was detected in 45 subjects, with an 
      extent of 13.3 +/- 15.2 g. At CMR-2, 53 (96.4%) patients had LGE, with an extent of 
      24.6 +/- 27.5 g. In 44 patients, LGE extent increased significantly (>/=1 g). 
      Patients with apical HCM had higher increments of LGE (p = 0.004) and LGE-rate (p 
      < 0.001) than those with other patterns of hypertrophy. The extent of LGE at 
      CMR-1 and the apical pattern of hypertrophy were independent predictors of the 
      increment of LGE. Patients with worsened New York Heart Association functional 
      class presented higher increase of LGE (p = 0.031) and LGE-rate (p < 0.05) than 
      those with preserved functional status. CONCLUSIONS: Myocardial fibrosis in HCM 
      is a progressive and fast phenomenon. LGE increment, related to a worse clinical 
      status, is more extensive in apical hypertrophy than in other patterns.
CI  - Copyright (c) 2012 American College of Cardiology Foundation. Published by Elsevier 
      Inc. All rights reserved.
FAU - Todiere, Giancarlo
AU  - Todiere G
AD  - Fondazione G. Monasterio CNR-Regione Toscana, Pisa, Italy.
FAU - Aquaro, Giovanni Donato
AU  - Aquaro GD
FAU - Piaggi, Paolo
AU  - Piaggi P
FAU - Formisano, Francesco
AU  - Formisano F
FAU - Barison, Andrea
AU  - Barison A
FAU - Masci, Pier Giorgio
AU  - Masci PG
FAU - Strata, Elisabetta
AU  - Strata E
FAU - Bacigalupo, Lorenzo
AU  - Bacigalupo L
FAU - Marzilli, Mario
AU  - Marzilli M
FAU - Pingitore, Alessandro
AU  - Pingitore A
FAU - Lombardi, Massimo
AU  - Lombardi M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Radiopharmaceuticals)
RN  - AU0V1LM3JT (Gadolinium)
SB  - IM
CIN - J Am Coll Cardiol. 2012 Sep 4;60(10):930-1. PMID: 22935465
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Cardiomyopathy, Hypertrophic/*pathology
MH  - Disease Progression
MH  - Female
MH  - Fibrosis
MH  - Gadolinium
MH  - Humans
MH  - *Magnetic Resonance Spectroscopy/methods
MH  - Male
MH  - Middle Aged
MH  - Myocardium/*pathology
MH  - Prognosis
MH  - Radiopharmaceuticals
MH  - Sample Size
MH  - Time Factors
MH  - Ventricular Dysfunction/etiology/pathology
EDAT- 2012/09/01 06:00
MHDA- 2012/11/03 06:00
CRDT- 2012/09/01 06:00
PHST- 2012/02/06 00:00 [received]
PHST- 2012/03/14 00:00 [revised]
PHST- 2012/03/29 00:00 [accepted]
PHST- 2012/09/01 06:00 [entrez]
PHST- 2012/09/01 06:00 [pubmed]
PHST- 2012/11/03 06:00 [medline]
AID - S0735-1097(12)02148-1 [pii]
AID - 10.1016/j.jacc.2012.03.076 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2012 Sep 4;60(10):922-9. doi: 10.1016/j.jacc.2012.03.076.